2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
2
Head and Neck Neoplasms
2
Voice Disorders
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomatitis
1
Squamous Cell Carcinoma of Head and Neck
1
Pleural Diseases
1
Papilloma
1
Ototoxicity
1
Mesothelioma
1
Laryngeal Neoplasms
1
Hearing Loss
1
Goiter
1
Esophageal Neoplasms
1
Deglutition Disorders
1
Cystitis, Interstitial
1
Arthralgia
1
Interventions
Gemcitabine
157
Cisplatin
117
pembrolizumab
81
Cystectomy
46
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Docetaxel
39
atezolizumab
33
Magnetic Resonance Spectroscopy
33
Radiotherapy
31
durvalumab
30
avelumab
26
BCG Vaccine
26
Specimen Handling
25
Cystoscopy
24
enfortumab vedotin
23
Doxorubicin
23
Fluorouracil
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Ipilimumab
14
Filgrastim
14
5-aminolevulinic acid hexyl ester
14
Transurethral Resection of Bladder
13
Surgical Procedures, Operative
13
Sunitinib
13
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Hyaluronic Acid
×
Clear all
NCT07495072
2026-03-27
PRO-GAG
BLAD-HYA Group
Phase NA
Recruiting
56 enrolled